| Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248) |
|---|
| 12/03/2009 | US20090297557 Human parvovirus: bocavirus |
| 12/03/2009 | US20090297556 Salmonella Based Oral Vaccines for Anthrax |
| 12/03/2009 | US20090297555 Recombinant human cytomegalovirus and vaccines comprising heterologous antigens |
| 12/03/2009 | US20090297554 Multi Plasmid System For The Production Of Influenza Virus |
| 12/03/2009 | US20090297553 Regimens for Immunisation With Meningococcal Conjugates |
| 12/03/2009 | US20090297552 Flagellin polypeptide vaccines |
| 12/03/2009 | US20090297551 Adjuvant |
| 12/03/2009 | US20090297550 Chloroplast-derived human vaccine antigens against malaria |
| 12/03/2009 | US20090297549 Conserved and specific streptococcal genomes |
| 12/03/2009 | US20090297548 Immunogenic compositions comprising anthrax spore-associated proteins |
| 12/03/2009 | US20090297547 Pharmaceutical composition containing the nmb0938 protein |
| 12/03/2009 | US20090297546 Avian-derived antibody capable of binding specifically to human hmgb1, immunological determination method for human hmgb1, and immunological determination reagent for human hmgb1 |
| 12/03/2009 | US20090297545 Immunomodulatory dairy peptides and uses thereof |
| 12/03/2009 | US20090297544 Novel tumor antigen protein sart-3 and tumor antigen peptides thereof |
| 12/03/2009 | US20090297543 Nucleophosmin protein (npm) mutants, corresponding gene sequences and uses thereof |
| 12/03/2009 | US20090297542 Adp-ribosylating toxin from listeria monocytogenes |
| 12/03/2009 | US20090297541 Maturation of dendritic cells |
| 12/03/2009 | US20090297540 Induction of Indoleamine 2,3-Dioxygenase in Dendritic Cells by TLR Ligands and Uses thereof |
| 12/03/2009 | US20090297539 Process for production of regulatory t cell |
| 12/03/2009 | US20090297538 Neurotoxic oligomers |
| 12/03/2009 | US20090297537 Combination therapy for the treatment of obesity and diabetes and conditions related thereto and for the treatment of conditions ameliorated by increasing a blood GLP-1 level |
| 12/03/2009 | US20090297536 Compositions, kits, and methods for identification, assessment, prevention and therapy of cancer |
| 12/03/2009 | US20090297535 Amino Acid Sequences Directed Against Il-6 And Polypetides Comprising The Same For The Treatment Of Diseases And Disorders Associated With Il-6 Mediated Signalling |
| 12/03/2009 | US20090297534 Catalytic Immunoglobulins BBK32 and Uses Therefor |
| 12/03/2009 | US20090297533 Controlled release immunomodulator compositions and methods for the treatment of otic disorders |
| 12/03/2009 | US20090297532 Antibody Neutralizers of Human Granulocyte Macrophage Colony Stimulating Factor |
| 12/03/2009 | US20090297531 Compositions and methods for the diagnosis and treatment of tumor |
| 12/03/2009 | US20090297530 Herv-k antigens, antibodies, and methods |
| 12/03/2009 | US20090297529 Anti-flt3 antibodies |
| 12/03/2009 | US20090297528 Methods to identify compounds useful for the treatment of proliferative and differentiative disorders |
| 12/03/2009 | US20090297527 Binding Domains of Proteins of the Repulsive Guidance Molecule (RGM) Protein Family and Functional Fragments Thereof, and Their Use |
| 12/03/2009 | US20090297526 Membranolytic Polypeptides and Methods of Use |
| 12/03/2009 | US20090297525 Compositions, kits and methods for identification, assessment, prevention and therapy of cancer |
| 12/03/2009 | US20090297524 Compositions monovalent for CD40L binding and methods of use |
| 12/03/2009 | US20090297523 Erm family binding agents and their use in diagnosis and treatment of proliferative conditions |
| 12/03/2009 | US20090297522 Recombinant human epo-fc fusion proteins with prolonged half-life and enhanced erythropoietic activity in vivo |
| 12/03/2009 | US20090297521 Cd33-specific single-chain immunotoxin and methods of use |
| 12/03/2009 | US20090297520 Methods of using conjugated toxin peptide therapeutic agents |
| 12/03/2009 | US20090297519 ANTINEOPLASTIC COMBINATIONS WITH mTOR INHIBITOR, TRASTUZUMAB, AND/OR HKI-272 |
| 12/03/2009 | US20090297518 Immunopotentiative composition |
| 12/03/2009 | US20090297517 Methods for treating il-18 mediated disorders |
| 12/03/2009 | US20090297516 Engineered lectins for viral inactivation |
| 12/03/2009 | US20090297515 Use of Caspase-8 Inhibitors for Modulating Hematopoiesis |
| 12/03/2009 | US20090297514 Humanization of antibodies |
| 12/03/2009 | US20090297513 Antibodies to il-6 and use thereof |
| 12/03/2009 | US20090297512 Compositions and methods for modulating vascular development |
| 12/03/2009 | US20090297511 Prevention and treatment of amyloidogenic disease |
| 12/03/2009 | US20090297510 Inhibition of calpain reduces allergic inflammation |
| 12/03/2009 | US20090297509 Treatment of human tumors with radiation and inhibitors of growth factor receptor tyrosine kinases |
| 12/03/2009 | US20090297508 Compositions and methods for treating hemostasis disorders associated with clec-2 signal transduction |
| 12/03/2009 | US20090297507 ADAM10 in Cancer Diagnosis, Detection and Treatment |
| 12/03/2009 | US20090297506 Classification of cancer |
| 12/03/2009 | US20090297505 Abeta binding molecules |
| 12/03/2009 | US20090297504 Bcma polypeptides and uses thereof |
| 12/03/2009 | US20090297503 Blood Coagulation Factor VIII Activation-Enhancing Antibodies |
| 12/03/2009 | US20090297502 Ccr2 antagonists for chronic organ transplantation rejection |
| 12/03/2009 | US20090297501 Structural Isomers of sc(Fv)2 |
| 12/03/2009 | US20090297500 NON-SMALL CELL LUNG CANCER-RELATED GENE, ANLN, AND ITS INTERACTION WITH RhoA |
| 12/03/2009 | US20090297479 Dc-hil conjugates for treatment of t-cell disorders |
| 12/03/2009 | US20090297473 Sulphonylpyrrole Hydrochloride Salts as Histone Deacetylases Inhibitors |
| 12/03/2009 | US20090297450 Tumor homing molecules, conjugates derived therefrom, and methods of using same |
| 12/03/2009 | US20090297449 Metalloproteinase 9 and metalloproteinase 2 binding proteins |
| 12/03/2009 | US20090297440 Gene Differentially Expressed in Breast and Bladder Cancer and Encoded Polypeptides |
| 12/03/2009 | US20090297438 Human Monoclonal Antibodies to Prostate Specific Membrane Antigen (PSMA) |
| 12/03/2009 | US20090297436 Antibodies to il-6 and use thereof |
| 12/03/2009 | CA2725947A1 Yeast strain for the production of proteins with terminal alpha-1,3-linked galactose |
| 12/03/2009 | CA2725613A1 Method of diagnosis of infection by mycobacteria and reagents therefor |
| 12/03/2009 | CA2721150A1 Indoleamine 2,3-dioxygenase based immunotherapy |
| 12/03/2009 | CA2721061A1 Treatment of thromboangiitis obliterans by removal of autoantibodies |
| 12/03/2009 | CA2717969A1 Vaccine for protection against lawsonia intracellulars |
| 12/02/2009 | EP2128261A1 A recombinant adenovirus comprising recombinant khp50 gene and preparation method and uses thereof |
| 12/02/2009 | EP2128257A2 Mutation of the parkin gene, compositions, methods and uses |
| 12/02/2009 | EP2128256A2 Molecular clones with mutated HIV GAG/POL, SIV GAG and SIV ENV genes |
| 12/02/2009 | EP2128253A1 Anti-fgf23 antibody and pharmaceutical composition comprising the same |
| 12/02/2009 | EP2128174A1 Multimeric forms of TNF superfamily ligands |
| 12/02/2009 | EP2127672A1 Inhibitor of herpesvirus infection, method for inhibition of herpesvirus infection, and use thereof |
| 12/02/2009 | EP2127671A1 Therapeutic agent for cancer |
| 12/02/2009 | EP2127670A1 Liposome for induction of cell-mediated immunity |
| 12/02/2009 | EP2127652A1 Method for treating cancer using anticancer agent in combination |
| 12/02/2009 | EP2126127A2 Use of anti-egfr antibodies in treatment of egfr mutant mediated disease |
| 12/02/2009 | EP2126086A1 Transcription factor for killer cell activation, differentiation and uses thereof |
| 12/02/2009 | EP2126055A1 Cancer disease modifying antibody 010207-01 produced by hybridoma cell line ar51a630.3. |
| 12/02/2009 | EP2126054A2 Redirected, genetically-engineered t regulatory cells and their use in suppression of autoimmune and inflammatory disease |
| 12/02/2009 | EP2125897A2 Monoclonal antibodies for treatment of cancer |
| 12/02/2009 | EP2125896A2 Anti-robo4 antibodies and uses therefor |
| 12/02/2009 | EP2125891A2 Antagonist ox40 antibodies and their use in the treatment of inflammatory and autoimmune diseases |
| 12/02/2009 | EP2125888A1 Method of providing human tumor-specific antibodies |
| 12/02/2009 | EP2125880A1 Soluble il-17ra/rc fusion proteins and related methods |
| 12/02/2009 | EP2125738A1 Immune response modifier compositions and methods |
| 12/02/2009 | EP2125500A2 Hiv combination vaccine and prime boost method |
| 12/02/2009 | EP2125033A2 Compositions and methods relating to organ-, tissue-, and cell-specific antibodies |
| 12/02/2009 | EP2125015A1 Method for the treatment of amyloidoses |
| 12/02/2009 | EP2125013A1 Dll4 signaling inhibitors and uses thereof |
| 12/02/2009 | EP2125011A2 Stimulation of an immune response by cationic lipids |
| 12/02/2009 | EP2125010A2 Treatment of immune disease by mucosal delivery of antigens using genetically modified lactobacillus |
| 12/02/2009 | EP2125009A1 Medicinal formulation containing a combination of hiv type i and hiv type ii |
| 12/02/2009 | EP2125006A2 Synthetic mini/micro-dystrophin genes to restore nnos to the sarcolemma |
| 12/02/2009 | EP2125005A2 Prame derived peptides and immunogenic compositions comprising these |
| 12/02/2009 | EP2124988A2 Methods to activate or block the hla-e/qa-1 restricted cd8+ t cell regulatory pathway to treat immunological disease |
| 12/02/2009 | EP2124986A2 Mycobacterium tuberculosis persistance genes |